First primary care clinic with VillageMD opens in Houston Walgreens

Walgreens has opened up the first in-store primary care clinic with VillageMD, a primary care company based in Chicago that operates nationally. The clinic, based in Houston, is one of five planned sites of care in the city.

The opening, which was announced via Twitter Nov. 20, is notable because Walgreens recently announced it was changing its in-store clinic strategy by closing its 160 owned and operated clinics and keeping open its 217 that operated by other healthcare providers. Its wholly owned in-store clinics operated at a loss to the company.

Walgreens had a network of 15 partners for in-store clinics, Alex Gourlay, co-chief operating officer, said during the company’s fourth quarter earnings call. The company also recently signed an agreement with TriHealth, a health system based in Cincinnati, to add 7 clinics.

Its partnership with VillageMD was announced in April 2019. The primary care clinics, which were described as state-of-the-art, are intended to operate next to five Walgreens stores within 2,5000 square feet, branded as Village Medical at Walgreens. The April announcement also teased potential for expansion in Houston and other markets.

“By adding primary care services to Walgreens, we are offering more options to give our customers a healthier and happier life,” Stephen Johnson, regional vice president of Walgreens, said during the ribbon cutting ceremony of the clinic on Nov. 20.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.